{"nctId":"NCT01763645","briefTitle":"A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer","startDateStruct":{"date":"2012-10","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"count":353,"armGroups":[{"label":"BCD-021 (CISC BIOCAD)","type":"EXPERIMENTAL","interventionNames":["Drug: Bevacizumab","Drug: Paclitaxel","Drug: Carboplatin"]},{"label":"Avastin (F. Hoffmann-La Roche Ltd)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bevacizumab","Drug: Paclitaxel","Drug: Carboplatin"]}],"interventions":[{"name":"Bevacizumab","otherNames":["Avastin","BCD-021"]},{"name":"Paclitaxel","otherNames":["Taxacad"]},{"name":"Carboplatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent;\n* Newly diagnosed histologically or cytologically confirmed NSCLC excluding squamous NSCLC (mixed cancer types should be classified according to the prevalent cell type);\n* IIIb or IV stage of NSCLC (TNM classification version 6);\n* Age ≥ 18 years and age ≤ 75 years (both inclusive);\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2, (not declining within 2 weeks prior to the first dose of investigational product);\n* Life expectancy - 12 weeks or more from the moment of randomization;\n* Presence of at least 1 measurable tumour with a size not less than 1 cm (revealed with CT slice thickness not more than 5 mm), as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria (specifically, no ascites, pleural, or pericardial effusions, osteoblastic bone metastases, or carcinomatous lymphangitis of the lung as only lesion;\n* Patients should be able to follow the Protocol procedures (according to Investigator's assessment);\n* Patients must implement reliable contraceptive measures during all the study treatment, starting 4 weeks prior to the administration of the first dose of investigational product until 6 months after the last dose of investigational product. This requirement does not apply to participants who have undergone surgical sterilization, or patients who are postmenopausal (documented) for the past 2 years. Reliable contraceptive measures include two methods of contraception, including one barrier method\n\nExclusion Criteria:\n\n* Squamous NSCLC;\n* Proven coagulopathy, clinically significant hemorrhage in the past including nasal hemorrhage;\n* absolute neutrophil count \\<1500/mm3;\n* Platelets \\<100 000/mm3;\n* Hemoglobin \\< 90 g/L;\n* Creatinine level ≥1.5 mg/dL;\n* Bilirubin level ≥1.5 × upper limit of normal (ULN);\n* Aspartate-aminotransferase(AST) and alanine-aminotransferase (ALT) levels ≥2.5 × ULN (≥5 × ULN for patients with liver metastases);\n* Alkaline phosphatase level ≥5 × ULN;\n* Current therapeutic anticoagulation treatment, aspirin (more than 325 mg/day), nonsteroidal anti-inflammatory drugs, antiplatelet agents or protracted treatment with these drugs less than 1 month before entering the study;\n* Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medical correction methods (low salt diet, physical exercise);\n* Any previous anticancer therapy (chemotherapy, radiation therapy , surgery etc.) of metastatic NSCLC;\n* Radiation or hormone therapy within 21 days prior to randomization;\n* Major surgery 28 days before inclusion into the study;\n* Previous antiangiogenic therapy;\n* Hypersensitivity to taxanes, platinum agents, recombinant murine proteins, contrast agents, premedication agents specified by Protocol (dexamethasone, diphenhydramine, ranitidine) or excipients of investigational products;\n* NSCLC metastases in central nervous system excluding metastases non-progressing without glucocorticosteroids within 4 weeks before inclusion into the trial;\n* Cardiovascular system pathology (CHF stage III-IV according to New York Heart Association (NYHA) classification);\n* Pregnancy or lactation;\n* Conditions limiting patient's adherence to Protocol requirements (dementia, neurologic or psychiatric disorders, drug addiction, alcoholism and others);\n* Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0;\n* Simultaneous participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial;\n* Any other concomitant cancer revealed within 5 years prior to screening, except curatively treated intraductal carcinoma in situ, curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma;\n* Acute or active chronic infections;\n* Hepatitis C virus, hepatitis B virus, HIV, or syphilis infections;\n* Obstacles in intravenous administration of study drugs","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.63","spread":null},{"groupId":"OG001","value":"33.82","spread":null}]}]}]},{"type":"PRIMARY","title":"Area Under the Curve After the First Test Drug Administration","description":"primary outcome measure for pharmacokinetics (PK) substudy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26951463","spread":null},{"groupId":"OG001","value":"23970112.875","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response Rate","description":"secondary outcome measure for efficacy evaluation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":null},{"groupId":"OG001","value":"1.79","spread":null}]}]}]},{"type":"SECONDARY","title":"Partial Response Rate","description":"secondary outcome measure for efficacy evaluation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.74","spread":null},{"groupId":"OG001","value":"37.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Stabilization Rate","description":"secondary outcome measure for efficacy evaluation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.85","spread":null},{"groupId":"OG001","value":"51.79","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Rate","description":"secondary outcome measure for efficacy evaluation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":null},{"groupId":"OG001","value":"8.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Anti-bevacizumab Antibodies","description":"Secondary outcome measure for immunogenicity assessment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":null},{"groupId":"OG001","value":"1.52","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":206},"commonTop":["Anaemia","Thrombocytopenia","Neutropenia","Leukopenia","Alopecia"]}}}